FGR Protein Expression in 91 Diffuse Large B-Cell Lymphoma Patients

A research paper analyzing FGR protein expression as a prognostic biomarker in diffuse large B-cell lymphoma (DLBCL). The study retrospectively evaluated 91 de novo DLBCL patients treated with first-line R-CHOP, finding high FGR expression in 70.3% of tumors and associating it with higher relapse rates. Authored by Kexin Shen and last updated on April 16, 2026, the work is shared under a CC-BY-4.0 license.

Use Cases

• Identify high-risk DLBCL patient subsets based on FGR protein expression levels described in the study.
• Validate prognostic models by comparing FGR expression against the International Prognostic Index (IPI) as discussed in the ROC analysis.
• Investigate the FGR/Src-family kinase axis as a candidate therapeutic target, as suggested in the conclusion.
• Analyze survival outcomes (PFS and OS) associated with biomarker expression in non-germinal center B-cell (non-GCB) subtypes.

Strengths

• Includes specific statistical results: high FGR expression was observed in 64 of 91 tumors (70.3%).
• Reports hazard ratios from multivariable analysis: HR 4.73 for inferior 5-year PFS.
• Provides external validation using a publicly available gene-expression dataset.
• Clear methodology described for immunohistochemistry scoring and survival analysis.

Limitations

• The dataset is a 696.5 KB DOCX file containing a research paper, not raw clinical or expression data.
• Row count and column-level documentation for any underlying data are unknown.
• The cohort size is limited to 91 patients from a single retrospective study.

Provenance

Source

figshare, author Kexin Shen.

Collection Method

Retrospective evaluation of FGR protein expression by immunohistochemistry in patient tumor samples.

Time Range

Study period not specified; data reflects treatment with first-line R-CHOP.

Freshness

Last updated 2026-04-16 04:19:34; freshness should be verified.

Geography

Geographic coverage of the patient cohort is not specified.